Flow-mediated dilation, nitroglycerin-mediated dilation and their ratio predict successful renal denervation in mild resistant hypertension
- 104 Downloads
Arterial hypertension is a major cardiovascular risk factor with a prevalence of about 30% in developed countries . Its effective treatment is essential to prevent complications such as myocardial infarction, stroke, or peripheral artery disease [2, 3]. 10–20% of hypertensive patients are classified as resistant hypertension, which is defined as hypertension treated with a minimum of three antihypertensive drugs at optimal dose, but still no substantial success in normalizing ambulatory blood pressure [4, 5]. Sympathetic nervous activity is one mechanism that underlies resistant hypertension . One treatment option for patients with resistant hypertension is catheter-based, renal artery denervation (RDN), which has been investigated in a variety of clinical trials in the past 10 years with constant confirmation of technical feasibility, but mixed results in terms of RDN-associated blood pressure reduction. The eligibility of patients for RDN strongly depends on sufficient...
Compliance with ethical standards
Conflict of interest
G.N. and N.W. received honoraria from Medtronic. M.S. and D.N. have no conflicts of interest.
- 3.Vegter EL, Ovchinnikova ES, van Veldhuisen DJ et al (2017) Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations. Clin Res Cardiol 106:598–609. https://doi.org/10.1007/s00392-017-1096-z CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Tsioufis C, Ziakas A, Dimitriadis K et al (2017) Erratum to: Blood pressure response to catheter-based renal sympathetic denervation in severe resistant hypertension: data from the Greek Renal Denervation Registry (Clin Res Cardiol, 10.1007/s00392-016-1056-z). Clin Res Cardiol 106:392. https://doi.org/10.1007/s00392-017-1084-3 CrossRefPubMedGoogle Scholar
- 17.Townsend RR, Mahfoud F, Kandzari DE et al (2017) Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. https://doi.org/10.1016/S0140-6736(17)32281-X CrossRefPubMedGoogle Scholar
- 18.Mahfoud F, Schmieder RE, Azizi M et al (2017) Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: State of the art and considerations for the future. Eur Heart J 38:3272–3281a. https://doi.org/10.1093/eurheartj/ehx215 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Dörr O, Liebetrau C, Möllmann H et al (2014) Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (Intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation. Hypertension 63:984–990. https://doi.org/10.1161/HYPERTENSIONAHA.113.02266 CrossRefPubMedGoogle Scholar